The Connection Between NCT01975831 and Mesothelioma
It is no secret that mesothelioma is a devastating form of cancer that can greatly impact the lives of patients and their families. Research into new treatments and therapies is ongoing, and NCT01975831 is one such study that has captured the attention of medical professionals and patients alike.
But what exactly is NCT01975831, and why is it such an important avenue of research for those impacted by mesothelioma? Let’s take a closer look at the study, its purpose, and how it may impact the future of mesothelioma treatment.
What is NCT01975831?
NCT01975831 is a clinical trial that aims to evaluate the efficacy and safety of a particular drug, known as defactinib or VS-6063, in treating malignant pleural mesothelioma. The study is currently being conducted at various centers across the United States and in several other countries.
The study is a phase 2 trial, which means that it is still in the early stages of research and development. However, if successful, it could pave the way for larger and more comprehensive studies that could ultimately lead to the approval of defactinib as a treatment for mesothelioma.
How Does Defactinib Work?
Defactinib is a type of drug known as a focal adhesion kinase inhibitor. This means that it works by blocking a particular enzyme that is crucial for the growth and survival of cancer cells. By inhibiting this enzyme, defactinib may be able to slow or halt the progression of mesothelioma, potentially improving patient outcomes and survival rates.
Who is Eligible for the Study?
Because NCT01975831 is a clinical trial, not everyone with mesothelioma will be eligible to participate. Participants must meet certain criteria, including having a histologically confirmed diagnosis of malignant pleural mesothelioma and having received prior treatment (such as chemotherapy) for the disease.
Other eligibility criteria may also apply, and interested patients should speak with their healthcare provider to determine if they may be a good fit for the study.
What is the Study Design?
NCT01975831 is a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to receive either a dose of defactinib or a placebo (an inactive substance), and neither the participant nor their healthcare provider knows which one they are receiving. This helps to eliminate bias and ensure that the study results are as accurate as possible.
Participants will receive either defactinib or placebo orally twice daily for 28-day cycles until disease progression or unacceptable toxicity occurs. Regular follow-up visits and assessments will be conducted throughout the study to monitor patient progress and safety.
What Are the Expected Results of the Study?
While no one can predict the exact results of NCT01975831, early indications are promising. A previous phase 1 trial of defactinib in mesothelioma patients showed promising results, with some patients experiencing disease stabilization or even partial responses to the treatment.
If the phase 2 trial is successful, it could pave the way for larger, more comprehensive studies that could ultimately lead to the approval of defactinib as a treatment for mesothelioma.
NCT01975831 and Mesothelioma: What You Need to Know
| Study Name | NCT01975831 |
|---|---|
| Drug Being Tested | Defactinib/VS-6063 |
| Purpose | To evaluate the efficacy and safety of defactinib in treating malignant pleural mesothelioma |
| Study Design | Randomized, double-blind, placebo-controlled |
| Eligibility Criteria | Must have histologically confirmed diagnosis of malignant pleural mesothelioma and have received prior treatment for the disease |
| Expected Results | If successful, could pave the way for larger, more comprehensive studies and ultimately lead to the approval of defactinib as a treatment for mesothelioma |
Frequently Asked Questions About NCT01975831 and Mesothelioma
What is the goal of NCT01975831?
The goal of NCT01975831 is to evaluate the safety and efficacy of defactinib in treating malignant pleural mesothelioma.
Who is eligible to participate in NCT01975831?
Participants must have a histologically confirmed diagnosis of malignant pleural mesothelioma and have received prior treatment for the disease. Other eligibility criteria may also apply.
What is the study design of NCT01975831?
NCT01975831 is a randomized, double-blind, placebo-controlled study. Participants are randomly assigned to receive either defactinib or a placebo.
What is defactinib?
Defactinib, also known as VS-6063, is a focal adhesion kinase inhibitor that works by blocking an enzyme crucial for the growth and survival of cancer cells.
What is malignant pleural mesothelioma?
Malignant pleural mesothelioma is a type of cancer that affects the lining of the lungs and chest cavity. It is most commonly caused by exposure to asbestos.
What are the potential benefits of participating in NCT01975831?
Participants in NCT01975831 may have access to a promising new treatment for mesothelioma that could potentially improve their outcomes and survival rates.
What are the potential risks of participating in NCT01975831?
As with any clinical trial, there may be potential risks and side effects associated with participating in NCT01975831. Participants should speak with their healthcare provider to fully understand the risks and benefits of participation.
How can I find out more about NCT01975831?
Interested individuals can visit clinicaltrials.gov to learn more about the study and eligibility criteria.
When will the results of NCT01975831 be available?
It is unclear when the results of NCT01975831 will be available, as the study is still ongoing. However, early indications are promising.
How can I get involved in mesothelioma research?
There are many ways to get involved in mesothelioma research, from participating in clinical trials to donating to research organizations. Speak with your healthcare provider or a mesothelioma advocacy group for more information.
How is mesothelioma typically treated?
Treatment for mesothelioma typically involves a combination of surgery, chemotherapy, and radiation therapy. However, new and innovative treatments are constantly being developed.
What are some common symptoms of mesothelioma?
Common symptoms of mesothelioma include shortness of breath, chest pain, coughing, and fatigue. However, symptoms may vary depending on the location and stage of the cancer.
Is mesothelioma always caused by asbestos exposure?
While asbestos exposure is the most common cause of mesothelioma, other factors such as radiation exposure and genetics may also play a role in the development of the disease.
How common is mesothelioma?
Mesothelioma is a relatively rare form of cancer, with approximately 3,000 new cases diagnosed in the United States each year.
How can I support someone with mesothelioma?
Supporting someone with mesothelioma can involve a variety of actions, from offering emotional support to helping with practical tasks. Speak with the individual to determine their needs and how you can best assist them.
The Future of Mesothelioma Treatment
NCT01975831 is just one of many ongoing studies and clinical trials that are working to make advancements in the treatment of mesothelioma. While more research is needed to fully understand the disease and develop effective treatments, studies like NCT01975831 offer hope and promise for patients and their families.
If you or a loved one has been impacted by mesothelioma, consider speaking with your healthcare provider or a mesothelioma advocacy group to learn more about ongoing research, clinical trials, and
other treatment options.
In Conclusion
NCT01975831 is an important clinical trial that holds great promise for the treatment of malignant pleural mesothelioma. While more research is needed, early indications are that defactinib may be a viable and effective treatment option for patients with this devastating disease. If you or a loved one has been impacted by mesothelioma, consider exploring opportunities for involvement in mesothelioma research and clinical trials, and don’t hesitate to speak with your healthcare provider about treatment options.
Take Action Today!
If you or a loved one has been diagnosed with mesothelioma, it is important to seek out available treatments and take proactive steps to manage the disease. Speak with your healthcare provider or a mesothelioma advocacy group to learn more about your options and get the support you need.
Closing and Disclaimer
This article is intended for informational purposes only and should not be construed as medical advice. Always speak with your healthcare provider before making any decisions about your health or treatment options.
